Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Low-income patients—and their health care providers—are less likely to challenge denials of their health insurance claims ...

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it’s not for the faint of heart. The digital health landscape is evolving, and investors might need to adapt.

Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss.

Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss.

Hims built its U.S. business by turning taboo subjects (hair loss, erectile dysfunction, anxiety) into approachable subscription kits, then upselling adjacent therapies once trust is established.

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.

Hims offers one of the fastest and easiest ways to get prescription medication for anxiety and depression. And it’s one of the only places where you can get a psychotropic medication ...

Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic.